Issue of Alcohol Dose dumping [Regulatives / Guidelines]

posted by Chiku – India, 2012-01-11 09:10 (5269 d 12:02 ago) – Posting: # 7896
Views: 11,850

Dear all,

Good morning!

We are developing XR generic formulation (market US). Our formulation is bioequivalent as well as F2 value is matching in all the required dissolution mediums.

The problem is we are failing in alcohol dose dumping study in 0.1 N HCl. what is the way out in this situation? wether regulatory (US FDA) will accept the dossier. Any justification can be provided?

Further i read the following thread
I get to understand EU's thinking but still confused about FDA's thinking. product developed is not opioid in this case.

In our case F2 value is not matching few other statistical methods for dissolution calculation shows similarity. based on this can i give justification? or else reformulation is the only way out? We used eudragit and Innovator has used HPMC polymer.


Thank you in anticipation!

Regards

Chiku:)


Copypasted last two paragraphs from a follow-up post. You can edit your own posts for 24 hours; no need to post a new one. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
109 visitors (0 registered, 109 guests [including 12 identified bots]).
Forum time: 22:12 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5